Acute pulmonary embolism (APE) is a very common form of venous thromboembolism that can be fatal if treatment is delayed. If APE is not treated, it results in death at a rate of 30%. Due to the vague symptoms of APE, the diagnosis may be delayed or the disease may be missed. Computed tomography angiography (CTA) is the gold standard for diagnosing APE. Also CTA is a valuable method in giving an idea about the severity of the disease. CTA shows the presence of thrombus in the pulmonary artery, which vessel it is in, and how much it occludes the vessel lumen. Due to various contraindications, lack of equipment or personnel, sometimes CTA cannot be performed in emergency services. Sometimes there are not qualified personnel to evaluate the CTA. For this reason, clinical scorings and risk factors that will facilitate the diagnosis of APE and give an idea about the severity of the disease are tried to be defined. However, none of them have sufficient specificity and sensitivity. There for there is a need for new biomarkers and clinical scorings that will facilitate the diagnosis of APE and predict the severity of the disease.